抗体生产市场规模、份额、成长分析、按产品、按工艺、按类型、按最终用途、按地区 - 行业预测，2024-2031 年

2022年全球抗体生产市场规模为164亿美元，从2023年的185.2亿美元增长到2031年的488.8亿美元，在预测期内（2024-2031年）预计复合年增长率为12.9%。

由于对抗体的需求不断增加，抗体生产市场正在经历显着增长，抗体对于标靶治疗、诊断和疫苗至关重要。生物技术的进步和对分子疾病机制的更深入了解正在增加对用于研究和个人化医疗的特异性和有效抗体的需求。慢性病和感染疾病流行继续推动这一需求，特别是对癌症和自体免疫疾病等治疗的需求。机会比比皆是，重组 DNA 技术和高通量筛检等创新提高了生产效率和扩充性。该市场在医疗保健行业中发挥着至关重要的作用，适应不断变化的需求，同时推动创新和扩张，以应对日益向精准医疗的转变。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管分析
• 案例研究分析
• 专利分析

抗体生产市场规模：依产品分类

• 市场概况
• 装置
  • 反应器
  • 多用途反应器
  • 反应器
  • 其他的
• 层析法系统
• 过滤系统
• 消耗品
  • 媒体
  • 缓衝液和试剂
  • 层析法树脂和管柱
  • 过滤耗材及配件
  • 其他的
• 软体

抗体生产市场规模：依製程分类

• 市场概况
• 上游加工
• 下游加工

抗体生产市场规模：按类型

• 市场概况
• 多株抗体
• 单株抗体

抗体生产市场规模：依最终用途分类

• 市场概况
• 製药和生物技术公司
• 研究室
• CROS 和 CDMOS

抗体生产市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Roche（Switzerland）
• Genmab（Denmark）
• Amgen（US）
• Biogen（US）
• Johnson & Johnson（US）
• AbbVie（US）
• AstraZeneca（UK）
• Novartis（Switzerland）
• Pfizer（US）
• Sanofi（France）
• Merck & Co.（US）
• Gilead Sciences（US）
• Celgene（US）
• BioMarin Pharmaceutical（US）
• Shire（Ireland）
• Alexion Pharmaceuticals（US）
• Teva Pharmaceuticals（Israel）
• Allergan（US）
• Bristol Myers Squibb（US）
• Novo Nordisk（Denmark）

结论和建议

Global Antibody Production Market size was valued at USD 16.4 billion in 2022 and is poised to grow from USD 18.52 billion in 2023 to USD 48.88 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2024-2031).

The antibody production market is witnessing significant growth, spurred by the rising demand for antibodies essential in targeted therapies, diagnostics, and vaccines. Advances in biotechnology and a deeper understanding of molecular disease mechanisms have heightened the need for specific and effective antibodies used in research and personalized medicine. The prevalence of chronic and infectious diseases continues to drive this demand, particularly for treatments in cancer, autoimmune disorders, and other conditions. Opportunities abound due to technological innovations, including recombinant DNA technology and high-throughput screening, which enhance production efficiency and scalability. This market plays a crucial role in the healthcare industry, adapting to evolving needs while fostering innovation and expansion in response to the increasing shift towards precision medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Production Market Segmental Analysis

Global Antibody Production Market is segmented by product, process, type, end use and region. Based on product, the market is segmented into instruments, chromatography systems, filtration systems, consumables and software. Based on process, the market is segmented into upstream processing and downstream processing. Based on type, the market is segmented into polyclonal antibody and monoclonal antibody. Based on end use, the market is segmented into pharmaceutical and biotechnology companies, research laboratories and cros and cdmos. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Production Market

The Global Antibody Production market is significantly driven by the escalating demand for antibody-based therapeutics, propelled by the rising incidence of chronic diseases and the widespread adoption of targeted treatment strategies. Antibodies are prized for their precision and effectiveness in managing a variety of health conditions, including cancer, autoimmune disorders, and infectious diseases. The emergence and application of monoclonal antibodies (mAbs) have transformed treatment modalities, leading to numerous blockbuster medications originating from antibody therapies. This increasing emphasis on specialized and efficient therapeutic options continues to bolster the market, reflecting the critical role of antibodies in modern medicine.

Restraints in the Global Antibody Production Market

The Global Antibody Production market faces significant restraints due to high development and production costs. The intricate processes involved in antibody development, coupled with extensive research and the need for expansive manufacturing facilities, lead to elevated expenses that can burden small and medium-sized enterprises. This cost-intensive nature of antibody production creates barriers to entry and diminishes the affordability and accessibility of antibody-based therapies, ultimately hampering market expansion. As a result, these economic challenges pose a substantial obstacle to growth within the industry, making it difficult for smaller players to compete and innovate in this evolving market landscape.

Market Trends of the Global Antibody Production Market

The Global Antibody Production market is witnessing a significant market trend driven by the increasing focus on personalized medicine. As healthcare systems shift towards more tailored treatment approaches, antibody production plays a pivotal role in creating targeted therapies designed to meet the unique needs of individual patients. Recent advancements in genomic and proteomic technologies have streamlined the identification of specific disease markers, enhancing the ability to design and manufacture antibodies that precisely target these markers. This alignment with personalized medicine not only fosters improved patient outcomes but also stimulates growth in the antibody production sector, as stakeholders increasingly prioritize customized therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Antibody Production Market Size by Product & CAGR (2024-2031)

• Market Overview
• Instruments
  • Bioreactors
  • Multi-Use Bioreactors
  • Single-Use Bioreactors
  • Others
• Chromatography Systems
• Filtration Systems
• Consumables
  • Media
  • Buffers and Reagents
  • Chromatography Resins and Columns
  • Filtration Consumables and Accessories
  • Others
• Software

Global Antibody Production Market Size by Process & CAGR (2024-2031)

• Market Overview
• Upstream Processing
• Downstream Processing

Global Antibody Production Market Size by Type & CAGR (2024-2031)

• Market Overview
• Polyclonal Antibody
• Monoclonal Antibody

Global Antibody Production Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Pharmaceutical and Biotechnology Companies
• Research Laboratories
• CROS and CDMOS

Global Antibody Production Market Size & CAGR (2024-2031)

• North America (Product, Process, Type, End Use)
  • USA
  • Canada
• Europe (Product, Process, Type, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Process, Type, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Process, Type, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Process, Type, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations